Indigofera

Indigofera tinctoria contains active compounds such as indigotin, indirubin, flavonoids, and alkaloids. Research suggests that indirubin may inhibit cyclin-dependent kinases, which contributes to potential anti-inflammatory and antineoplastic effects. Additionally, the flavonoids and tannins provide antioxidant properties that support traditional hepatoprotective uses. However, specific human clinical mechanisms remain under-researched, and current evidence is limited (Evidence Level C).

Yes, Indigofera tinctoria may interact with anticonvulsant medications. While the herb has been used in folk medicine for epilepsy, combining it with pharmaceutical anticonvulsants could lead to additive effects or reduced drug efficacy. Because of the potential for serious neurological interactions, individuals taking prescription seizure medications should avoid this herb unless supervised by a qualified healthcare provider.

The typical adult dosage for Indigofera tinctoria is 2 to 3 grams of the dried herb prepared as a tea. For external applications, such as treating skin conditions or dyeing hair, the leaves are often applied as a paste or wash. Due to limited clinical safety data, users should adhere to traditional dosing guidelines and avoid excessive consumption to prevent gastrointestinal side effects.

No, Indigofera tinctoria is considered unsafe during pregnancy. Traditional use and safety classifications contraindicate its use for pregnant women due to the presence of alkaloids and other compounds that may pose toxicity risks or stimulate uterine contractions. Women who are pregnant or breastfeeding should strictly avoid internal consumption and consult a professional before topical use.

Indigofera tinctoria has been cultivated for centuries primarily as a source of natural indigo dye. In traditional Indian and East Asian medicine, the leaves are utilized to support liver and spleen health and to treat various skin conditions. Folk medicine also suggests its use for epilepsy, though scientific validation for these specific indications remains limited (Evidence Level C).